NanoViricides (NNVC) Stock

SHELTON, CT / ACCESSWIRE / December 23, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug. "Despite all changes, the H5N1 Influenza A virus should remain susceptible to NV-387 because NV-387 mimics the very essential host-side feature that H5N1 continues to use even as it changes," said Anil R.

The rise of unexplained human cases of bird flu in North America means there is an urgent need for effective treatments that can withstand viral mutations. In this opinion article, Anil Diwan, CEO of NanoViricides (NYSE-A:NNVC), a clinical-stage nano-biopharmaceutical company that develops and commercializes drugs designed to treat viral infections, raises alarm over the evolving threat of H5N1 bird flu, highlighting recent research that shows the virus is just one mutation away from effectively targeting human cells.

NanoViricides (NYSE-A:NNVC) reported progress on its lead antiviral drug NV-387 and revealed plans to advance Phase II clinical trials for MPox and RSV. The Shelton, Connecticut-based company is waiting for results from its Phase I trial of NV-387 and has taken steps towards starting a Phase II trial of NV-387 for the treatment of MPox infection in Central Africa.

SHELTON, CT / ACCESSWIRE / November 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending September 30, 2024 with the Securities and Exchange Commission (SEC) on Thursday, November 14, 2024. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000141057824001991/nnvc-20240930x10q.htm).

SHELTON, CT / ACCESSWIRE / November 4, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.

SHELTON, CT / ACCESSWIRE / October 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.

Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR SHELTON, CT / ACCESSWIRE / October 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D.

NanoViricides (NYSE-A:NNVC) filed its annual report, announcing that its broad-spectrum antiviral NV-387 is progressing to Phase II clinical trials, with potential indications including RSV, influenza, MPOX/smallpox, and COVID-19. NV-387 has demonstrated broad-spectrum efficacy in preclinical trials against viruses such as COVID-19, RSV, and influenza.

SHELTON, CT / ACCESSWIRE / September 30, 2024 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2024 with the Securities and Exchange Commission (SEC) on Friday, September 27, 2024. The report can be accessed at the SEC website ( https://www.sec.gov/ix?doc=/Archives/edgar/data/1379006/000141057824001650/nnvc-20240630x10k.htm ).